ASTRAZENECA PLC — 6-K Filings
1,550 6-K filings on record
This page lists all 6-K filings submitted to the SEC by ASTRAZENECA PLC (AZN), sorted by most recent first. Each row links to the full filing on EdgarLookup. ASTRAZENECA PLC has filed 1,550 6-K documents with the SEC since 2018. To view all SEC filings by ASTRAZENECA PLC, see the full filings list.
All
11-K
144
20-F
20-F/A
25
25-NSE
3
3/A
4
424B2
424B3
424B5
425
6-K
6-K/A
8-A12B
8-A12B/A
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3ASR
F-4
F-4/A
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
NO ACT
S-1
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS | 0001654954-26-002860 | Mar 27, 2026 | — |
| 6-K | NOTIFICATION OF ADMISSION OF SHARES | 0001654954-26-002523 | Mar 20, 2026 | — |
| 6-K | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER | 0001654954-26-002272 | Mar 16, 2026 | — |
| 6-K | NOTICE OF AGM | 0001654954-26-002077 | Mar 10, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-025559 | Mar 10, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001963 | Mar 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001966 | Mar 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001961 | Mar 6, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-001728 | Mar 2, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-022240 | Mar 2, 2026 | — |
| 6-K | ASTRAZENECA PRICES A $2BN BOND OFFERING | 0001654954-26-001589 | Feb 26, 2026 | — |
| 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-26-001536 | Feb 25, 2026 | — |
| 6-K | DIRECTORATE CHANGE | 0001654954-26-001481 | Feb 24, 2026 | — |
| 6-K | ANNUAL FINANCIAL REPORT | 0001654954-26-001483 | Feb 24, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-019110 | Feb 24, 2026 | — |
| 6-K | FIXED-DURATION CALQUENCE COMBO APPROVED IN US | 0001654954-26-001409 | Feb 20, 2026 | — |
| 6-K | FINAL RESULTS | 0001654954-26-001073 | Feb 10, 2026 | — |
| 6-K | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION | 0001654954-26-000857 | Feb 3, 2026 | — |
| 6-K | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | 0001654954-26-000795 | Feb 2, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000824 | Feb 2, 2026 | — |
| 6-K | ASTRAZENECA BEGINS TRADING ON NYSE | 0001654954-26-000792 | Feb 2, 2026 | — |
| 6-K | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC | 0001654954-26-000730 | Jan 30, 2026 | — |
| 6-K | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 | 0001654954-26-000688 | Jan 29, 2026 | — |
| 6-K | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE | 0001654954-26-000464 | Jan 20, 2026 | — |
| 6-K | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | 0001654954-26-000153 | Jan 8, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000027 | Jan 2, 2026 | — |
| 6-K | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | 0001654954-25-014166 | Dec 22, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014171 | Dec 22, 2025 | — |
| 6-K | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | 0001654954-25-014164 | Dec 22, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014136 | Dec 19, 2025 | — |
| 6-K | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | 0001654954-25-013970 | Dec 16, 2025 | — |
| 6-K | SUBCUTANEOUS SAPHNELO APPROVED IN EU | 0001654954-25-013974 | Dec 16, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-013678 | Dec 4, 2025 | — |
| 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-25-013569 | Dec 1, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-013567 | Dec 1, 2025 | — |
| 6-K | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | 0001654954-25-013450 | Nov 26, 2025 | — |
| 6-K | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | 0001654954-25-013401 | Nov 24, 2025 | — |
| 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE US | 0001654954-25-013317 | Nov 20, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-013129 | Nov 17, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013043 | Nov 14, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-012757 | Nov 10, 2025 | — |
| 6-K | 9M AND Q3 2025 RESULTS | 0001654954-25-012630 | Nov 6, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-105425 | Nov 3, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-012498 | Nov 3, 2025 | — |
| 6-K | RESULT OF GENERAL MEETING | 0001654954-25-012502 | Nov 3, 2025 | — |
| 6-K | DIRECTOR DECLARATION | 0001654954-25-012271 | Oct 28, 2025 | — |
| 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | 0001654954-25-012262 | Oct 28, 2025 | — |
| 6-K | TEZSPIRE APPROVED IN EU FOR CRSWNP | 0001654954-25-012040 | Oct 22, 2025 | — |
| 6-K | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | 0001654954-25-011943 | Oct 20, 2025 | — |
| 6-K | US FDA APPROVES TEZSPIRE IN CRSWNP | 0001654954-25-011951 | Oct 20, 2025 | — |